SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd ($INDO) is a top trending energy stock as escalating geopolitical tensions in the Middle East, including reported strikes on oil infrastructure and fears of supply disruption, fuel community speculation about its potential for a major rally, despite active profit-taking and volatility.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is trending as escalating Middle East tensions drive up oil prices, with the community actively discussing its substantial price action and anticipating a significant short squeeze due to high borrow rates and minimal shares available to short.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing extreme volatility and a major sell-off following a Raymond James downgrade, fueled by the U.S. Space Force's decision to re-compete the critical $1.4 billion SCAR program, leaving the community debating whether the contract is lost or merely undergoing renegotiation for this drone defense leader.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is a central topic of discussion amid rising geopolitical tensions and the US Army's "Drone Dominance Program," with the community actively speculating on unprecedented demand for its drone and robotic solutions. Recent institutional boosts and public endorsements from military figures are fueling excitement for potential significant government contracts.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp. is trending as escalating geopolitical tensions are amplifying urgent discussions around domestic critical mineral supply chains for military munitions. The community is highlighting UAMY's unique position as the only US antimony producer, anticipating government contracts and funding to secure this vital resource amidst global supply pressures.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as recent weaker operating earnings and a substantial cash pile fuel community debate over whether the leadership transition to Greg Abel signals a shift towards more active capital deployment or if the conglomerate risks its "safe haven" reputation amidst market volatility.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as escalating Middle East tensions, including a halt in Qatar's LNG production, drive a sharp rise in global natural gas prices, favorably positioning the company's significant spot market exposure and rapidly expanding capacity. The community remains bullish, actively discussing its long-term value and project milestones like CP2, often viewing recent analyst downgrades as attempts to acquire cheaper shares.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Speculation is rampant around POET Technologies as NVIDIA's increasing focus on optical interconnects for AI data centers and Marvell's acquisition of Celestial AI validate the photonics sector, with the community anticipating significant partnership announcements and a revenue ramp, potentially coinciding with the upcoming OFC conference.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is seeing significant upward momentum driven by intense anticipation for its Phase 3 REGAL trial results for the cancer therapy GPS, which many in the community believe will show overwhelming efficacy due to the extended trial duration. This sentiment, combined with strong speculation of an imminent short squeeze and a potential buyout by a major pharmaceutical firm, is fueling a fierce battle around the $5 price level.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after delivering a strong Q4 earnings beat and optimistic 2026 revenue guidance, significantly amplified by a competitor's FDA rejection for a Cushing's syndrome drug, which positions Recorlev for expanded market leadership. Despite an apparent market overreaction, the community sees this as a prime buying opportunity given the company's high gross margins, path to profitability, and advancing blockbuster pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behet's Disease

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behet's Disease Soligenix Receives Positive Opinion...

Soligenix to Present at BIO Investment & Growth Summit

Soligenix to Present at BIO Investment & Growth Summit Soligenix to Present at BIO Investment & Growth Summit PR Newswire PRINCETON, N.J., Feb. 24, 2026 PRINCETON, N.J., Feb. 24, 2026 /PRNewswire...

Soligenix Details Recent Progress and Upcoming Milestones

Soligenix Details Recent Progress and Upcoming Milestones Soligenix Details Recent Progress and Upcoming Milestones PR Newswire PRINCETON, N.J., Feb. 12, 2026 PRINCETON, N.J., Feb. 12, 2026...

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Soligenix reports positive Phase 2a extension results for SGX302 gel in psoriasis, showing improved skin scores and strong tolerability.read more...

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis Soligenix Announces Top-line Results of the Phase 2a Study of...

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Soligenix Achieves Enrollment...

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma PR Newswire PRINCETON, N.J...

Shares of Soligenix rallied sharply on Tuesday, marking their best performance in nearly two months, after the biopharmaceutical company reported a key safety milestone in its confirmatory Phase 3 FLASH2 trial evaluating HyBryte (synthetic hypericin) for treating cutaneous T-cell lymphoma (CTCL).The stock jumped 20% to $1.64 on Tuesday, and added another 0.9% after hours in continued upbeat trading.The company said its first Data Monitoring Committee (DMC) meeting for the study concluded that there were no safety concerns, with HyBryte’s safety profile consistent with prior trials.&nbsp;The committee’s conclusion allows the trial to move ahead as planned, with enrollment proceeding well and an update expected in the fourth quarter of 2025, followed by a blinded interim efficacy analysis in the first half of 2026.The ongoing FLASH2 trial is a randomized, double-blind, placebo-controlled, multicenter study enrolling about 80 patients with early-stage CTCL. The study builds on Soligenix’s previous successful Phase 3 FLASH trial, which showed a 49% treatment response after 18 weeks of therapy.&nbsp;FLASH2 extends continuous double-blind treatment to 18 weeks, designed to demonstrate the drug’s effect over a more “real-world” course.HyBryte, which uses visible light-activated synthetic hypericin applied topically to skin lesions, has received orphan drug and fast-track designations from the FDA, along with&nbsp;an orphan designation from the European Medicines Agency (EMA). The company stated that its light-activated mechanism enables deeper penetration into skin tissue without causing DNA damage, positioning it as a potentially safer frontline therapy for CTCL.On Stocktwits, retail sentiment for Soligenix was ‘extremely bullish’ amid a 2,025% surge in 24-hour message volume.One bullish user described the latest Soligenix update as a strong catalyst, saying the stock appeared ready to rebound sharply after the morning dip and could test new highs in the coming sessions.&nbsp;<stembedurl>https://stocktwits.com/LithiumMakesMeHard/message/631396013</stembedurl>Another bullish user noted that the price action suggested momentum might continue, with potential for a multiday run.<stembedurl>https://stocktwits.com/bzspy/message/631352248</stembedurl><a href="https://stocktwits.com/symbol/SNGX">Soligenix’s stock</a> has declined 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Soligenix’s stock (SNGX) has declined 39% so far in 2025. (Photo credit: Getty Images)

Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally

The company said enrollment in its Phase 3 HyBryte study is progressing well, with an interim efficacy analysis planned for the first half of 2026. 

Equity

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Soligenix Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Current Price	$1.13
Prev Close	$1.18
Open	$1.16
Dividend Yield	0.00%
50-Day Moving Average	$1.28
Beta	0.53
Avg. Volume	191,284.15
PE Ratio	-0.32

52-Week High	$6.23
52-Week Low	$1.02
Market Capitalization	$11.9M
EPS (Annual)	-$4.98
Price to Book	1.53
Revenue Per Employee	$0.00

SNGX
Soligenix Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SNGX News

SNGXSoligenix Inc